EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

Intratumoral oncolytic virotherapy in pancreatic cancer: from feasibility to immune priming

Tsutomu Nishida iD, Yoshito Hayashi iD

Translational Gastroenterology and Hepatology · 2026-05 · 11 · 56-56

DOI: 10.21037/tgh-2026-0010 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-05. Verfasst von Tsutomu Nishida und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

overall survival of 7.8 months—but also in its acceptable safety profile and demonstration of technical feasibility and biological plausibility. Intratumoral delivery via EUS has the potential to circumvent one of the central barriers in PDAC therapy, poor drug penetration due to stromal desmoplasia, while simultaneously providing a means to remodel the tumor immune microenvironment. However, the absence of objective responses warrants careful interpretation. T-VEC is designed to induce local viral replication, tumor cell lysis, and antigen release; however, these processes do not necessarily translate directly into measurable tumor shrinkage. In PDAC, even when local oncolysis and immune

Schlagwörter

Stichwörter der Autor:innen

Pancreatic ductal adenocarcinoma (PDAC)immune primingintratumoral immunotherapyoncolytic virotherapytalimogene laherparepvec (T-VEC)

Autor:innen und Institutionen

  • Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Osaka, Japan.

ORCID-Profile: Tsutomu Nishida, Yoshito Hayashi

Zitieren

APA

Nishida, T., & Hayashi, Y. (2026). Intratumoral oncolytic virotherapy in pancreatic cancer: from feasibility to immune priming. Translational Gastroenterology and Hepatology, 11, 56-56. https://doi.org/10.21037/tgh-2026-0010

Vancouver

Nishida T, Hayashi Y. Intratumoral oncolytic virotherapy in pancreatic cancer: from feasibility to immune priming. Translational Gastroenterology and Hepatology. 2026;11:56-56. doi:10.21037/tgh-2026-0010

BibTeX
@article{Nishida2026,
  author = {Nishida, Tsutomu and Hayashi, Yoshito},
  title = {Intratumoral oncolytic virotherapy in pancreatic cancer: from feasibility to immune priming},
  journal = {Translational Gastroenterology and Hepatology},
  year = {2026},
  volume = {11},
  pages = {56--56},
  doi = {10.21037/tgh-2026-0010}
}
Kostenlos starten →